

POLICY NAME	Tzield (teplizumab)	POLICY #	
Criteria			
Exclusion Criteria – Any of the following prevents coverage			
<input type="checkbox"/> 2.1 Type 1 diabetes stage 3			
<input type="checkbox"/> 2.2 Type 2 diabetes			
Coverage Criteria			
<input type="checkbox"/> 1.1 Documented diagnosis of stage 2 type 1 diabetes at risk for progressing to clinical disease as supported by all of the following: <ul style="list-style-type: none">• Presence of at least two positive pancreatic islet autoantibody samples within the past 6 months (examples of antibodies include glutamic acid decarboxylase 65 (GAD) autoantibody, insulin autoantibody (IAA), insulinoma-associated antigen 2 autoantibody (IA-2A), zinc transporter 8 autoantibody (ZnT8A), islet cell autoantibody (ICA).• Presence of abnormal blood sugar levels without always high blood sugar levels• Family relative with type 1 diabetes			
<input type="checkbox"/> 1.2 Prescribed by or in consultation with an endocrinologist (hormone doctor)			
<input type="checkbox"/> 1.3 Age 8 years or older			
<input type="checkbox"/> 1.4 Clinical review for coverage is completed by both a pharmacist and medical director			

Criteria

Exclusion Criteria – Any of the following prevents coverage

- ☐ 2.1 Type 1 diabetes stage 3
- ☐ 2.2 Type 2 diabetes

Coverage Criteria

- ☐ 1.1 Documented diagnosis of stage 2 type 1 diabetes at risk for progressing to clinical disease as supported by all of the following:
 - Presence of at least two positive pancreatic islet autoantibody samples within the past 6 months (examples of antibodies include glutamic acid decarboxylase 65 (GAD) autoantibody, insulin autoantibody (IAA), insulinoma-associated antigen 2 autoantibody (IA-2A), zinc transporter 8 autoantibody (ZnT8A), islet cell autoantibody (ICA).
 - Presence of abnormal blood sugar levels without always high blood sugar levels
 - Family relative with type 1 diabetes
- ☐ 1.2 Prescribed by or in consultation with an endocrinologist (hormone doctor)
- ☐ 1.3 Age 8 years or older
- ☐ 1.4 Clinical review for coverage is completed by both a pharmacist and medical director